NovoCure
Open
$14.88
Prev. Close
$14.88
High
$14.88
Low
$14.88
Market Snapshot
$1.34B
-9.8
-1.56
$605.22M
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
emptyResult
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Recently from Cashu
NovoCure Achieves 74.4% Disease Control Rate, Signaling Breakthrough in Cancer Treatment
NovoCure Shows Strong Progress in Disease Control Rates NovoCure is making notable advancements in its research and development efforts, as evidenced by a recent announcement detailing a disease contr…
NovoCure Reports Q4 Growth Amid Innovation in Cancer Treatment Strategies
NovoCure's Q4 Earnings Reflect Growth Amid Ongoing Innovation NovoCure (NASDAQ: NVCR) showcases promising growth in its Q4 earnings report, reflecting a total revenue of $140 million, which marks a si…
Oncolytics Biotech Advances in Immuno-Oncology with Promising Drug Pelareorep
Oncolytics Biotech's Strategic Advances in Immuno-Oncology Oncolytics Biotech Inc. is making significant strides in the immuno-oncology sector as it lays the groundwork for a strong position in a mark…
NovoCure Targets Oncology Growth with Innovative Therapies and Strong Revenue Increase
NovoCure Navigates Expanding Oncology Market with Innovative Therapies NovoCure, a pioneering leader in cancer treatment, is actively exploring opportunities to enhance its position within the growing…